SUNPHARMA2022-01-012022-03-31in-bse-fin:OneOperatingExpenses01Member SUNPHARMA2022-01-012022-03-31in-bse-fin:OneOperatingExpenses02Member SUNPHARMA2022-01-012022-03-31in-bse-fin:FourOperatingExpenses01Member SUNPHARMA2022-01-012022-03-31in-bse-fin:FourOperatingExpenses02Member SUNPHARMA2022-01-012022-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SUNPHARMA2022-01-012022-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SUNPHARMA2022-01-012022-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member SUNPHARMA2022-01-012022-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SUNPHARMA 2021-04-01 2022-03-31 2022-05-12 INR Millions Yearly true Cash Flow Indirect Single segment Pharmaceuticals 2022-01-01 2022-03-31 Audited Standalone 40068800000.00 3004100000.00 43072900000.00 12862400000.00 2378400000.00 -1501300000.00 4979400000.00 911900000.00 3541400000.00 11351500000.00 34523700000.00 8549200000.00 -16549600000.00 -8000400000.00 455700000.00 4406000000.00 4861700000.00 0.00 -12862100000.00 0.00 0.00 0.00 0.00 -12862100000.00 -431300000.00 -13293400000.00 0.00 0.00 2399300000.00 1 -5.40 -5.40 0.00 0.00 -5.40 -5.40 0.00 0.00 0.00 1. The above audited standalone financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 30, 2022. 2. The above audited standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3. Pursuant to the Scheme of Amalgamation and Merger of Sun Pharma Global FZE, with the Company, as approved by the National Company Law Tribunal on August 31, 2021, Sun Pharma Global FZE, merged with the Company w.e.f. January 01, 2020. The effect of this merger including the tax impact was given in the financial results of the year ended March 31, 2022 in accordance with Ind AS 103 – Business Combinations. The results for previous periods have been restated to give effect to the merger. 4.Exceptional items includes a) On March 25, 2021 the CJEU (Court of Justice to the European Union) issued a final judgment and upheld the European Commission’s ( EC ) decision dated June 19, 2013 that a settlement agreement between Ranbaxy (U.K.) Limited and Ranbaxy Laboratories Limited (together Ranbaxy ) with Lundbeck was anti-competitive. Ranbaxy had made a provisional payment of the fine of Euros 10.3 Million on September 20, 2013. Since there were no further rights of appeal, this amount of INR 895.6 Million (inclusive of legal charges) was debited to the audited standalone financial results for the year ended March 31, 2021. b) Results for the year ended March 31, 2022 include a charge of INR 1,655.7 Million towards impairment of an acquired intangible asset under development. c) The Company and certain of its subsidiaries are defendants in a number of class action lawsuits brought by purchasers and payors in the U.S. alleging violation of antitrust laws with respect to its ANDAs for Valganciclovir, Valsartan and Esomeprazole. The cases were transferred to the U.S. District Court for the District of Massachusetts for coordinated proceedings. With a view to resolve the dispute and avoid uncertainty, a settlement without any admission of guilt or violation of any statute, law, rule or regulation, or of any liability or wrongdoing was reached with all of the plaintiff classes on March 23, 2022, for a total settlement amount of USD 485 Million of which USD 210 Million was borne by the Company along with its related legal charges of USD 8.3 Million pertaning to this lawsuit (equivalent to INR 16,549.6 Million inclusive of legal charges). The settlement is subject to final approval by the Court. d) Consequent to the settlement of lawsuit mentioned in 4(c) above, during the quarter and year ended March 31, 2022, the Company has reassessed the expected timing of utilisation of Minimum Alternate Tax (MAT) credit and based on this reassessment written off a MAT credit of INR 4,406.0 Million and disclosed the charge as an exceptional item. For Note 5-12 Kindly refer the financial results submitted to the exchange within 30 minutes. Single segment 2021-04-01 2022-03-31 Audited Standalone 155859800000.00 9579200000.00 165439000000.00 45849700000.00 12486000000.00 -1831800000.00 20007800000.00 3881000000.00 13499500000.00 50272900000.00 144165100000.00 21273900000.00 -18205300000.00 3068600000.00 -337500000.00 4406000000.00 4068500000.00 0.00 -999900000.00 0.00 0.00 0.00 0.00 -999900000.00 -916200000.00 -1916100000.00 0.00 0.00 2399300000.00 1 243480200000.00 -0.40 -0.40 0.00 0.00 -0.40 -0.40 0.00 0.00 0.00 Net (gain) / loss on foreign currency transactions -1400800000.00 Other Expenses 12752300000.00 Net (gain) / loss on foreign currency transactions -2389600000.00 Other Expenses 52662500000.00 3881000000.00 196800000.00 23384400000.00 0.00 2561100000.00 0.00 0.00 0.00 0.00 -13388600000.00 0.00 15187000000.00 0.00 13499500000.00 0.00 11096000000.00 0.00 0.00 0.00 444200000.00 135400000.00 4390200000.00 0.00 -500000.00 0.00 -2198400000.00 0.00 1562700000.00 0.00 51699600000.00 54768200000.00 0.00 0.00 0.00 -21595400000.00 0.00 76363600000.00 0.00 0.00 71507800000.00 69645300000.00 0.00 0.00 0.00 0.00 465000000.00 8499000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 28302300000.00 8129000000.00 0.00 0.00 135400000.00 226000000.00 0.00 -1037600000.00 0.00 -27021000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 85611200000.00 108836900000.00 0.00 370200000.00 21589200000.00 3523400000.00 0.00 0.00 -48708500000.00 634100000.00 50600000.00 684700000.00 3510600000.00 4195300000.00